The UK and US have agreed to a key bilateral deal that will ensure no import taxes on UK pharmaceutical shipments being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these crucial exports will be held at nothing for a period of the next three years.
This development follows previous threats to dramatically increase duties on patented drug products, with figures floated reaching one hundred percent.
"This agreement between the Britain strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic drug exports," an announcement said.
Trade Importance
Drugs represent one of the Britain's biggest exports to the United States, which is by far the largest market for leading British pharmaceutical firms.
Statistics show that in the year prior to September, the UK shipped drugs totaling £11.1bn to the US. This figure represented a significant portion of total UK exports in that span.
"This deal safeguards work, increases investment and paves the way for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement involves several key changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to raise total public funding on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. In the past, refunds were more than 20%.
Broader Context
The deal follows a long-running dispute between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were heightened by arguments that US patients were paying several times more for the identical medicines than people in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the last ten years.
